| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T246 |
0-194 |
Sentence |
denotes |
In the light of collected data, despite the success of the first clinical trials, the latest studies have shown the ineffectiveness of HCQ for the treatment and prevention of COVID-19 infection. |
| T247 |
195-215 |
Sentence |
denotes |
So that, if the U.S. |
| T248 |
216-509 |
Sentence |
denotes |
Food and Drug Administration (FDA) had initially authorized the use of HCQ in case of emergency [61], in June 2020, the FDA revoked this authorization [62] since the potential HCQ effectiveness in treating COVID-19 was overtaken by severe cardiac adverse events and other serious side effects. |
| T249 |
510-753 |
Sentence |
denotes |
In fact, there is the need to consider that in subjects with severe COVID-19, the abundance of inflammatory molecules like interleukins and tumor necrosis factors generate a cytokine storm, leading to a septic shock and multiple organ failure. |
| T250 |
754-860 |
Sentence |
denotes |
In hepatic and renal dysfunction, HCQ metabolism and clearance were compromised and its safety is altered. |
| T251 |
861-1096 |
Sentence |
denotes |
Moreover, recently the Surviving Sepsis Campaign guidelines on the management of critically ill patients with COVID-19 concluded that there was insufficient evidence to recommend the routine use of HCQ in patients admitted in ICU [63]. |
| T252 |
1097-1224 |
Sentence |
denotes |
In the same way, the American College of Physicians practice guidelines do not recommend HCQ for prophylaxis or treatment [64]. |
| T253 |
1225-1485 |
Sentence |
denotes |
International trials like SOLIDARITY (International trial by World Health Organisation) [65], RECOVERY (Randomised Evaluation of Covid-19 Therapy) [66], and DISCOVERY (Trial of Treatments for COVID-19 in Hospitalized Adults) [67] have also stopped the HCQ arm. |
| T254 |
1486-1716 |
Sentence |
denotes |
In particular, the World Health Organisation (WHO), in the SOLIDARITY trial project, has arrested all arms involving HCQ, as evidence showed that it did not reduce the mortality of hospitalized COVID-19 patients compared with SOC. |
| T255 |
1717-1856 |
Sentence |
denotes |
However, this decision was not applied to HCQ use or evaluation in pre- or post-exposure prophylaxis for subjects exposed to COVID-19 [68]. |
